SynAct Pharma AB (STO:SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
20.60
-0.10 (-0.48%)
Feb 10, 2026, 5:29 PM CET
Market Cap1.10B +105.2%
Revenue (ttm)n/a
Net Income-106.28M
EPS-2.21
Shares Out53.33M
PE Ration/a
Forward PE76.92
Dividendn/a
Ex-Dividend Daten/a
Volume118,863
Average Volume149,030
Open20.70
Previous Close20.70
Day's Range20.35 - 20.95
52-Week Range13.40 - 25.30
Beta1.06
RSI40.32
Earnings DateFeb 18, 2026

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 8
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements